Is Aptevo Therapeutics Inc (APVO) overvalued? · rev $3.1M
Aptevo Therapeutics Inc (APVO) is a biotechnology company listed on US.
This page asks whether Aptevo Therapeutics Inc (APVO) looks expensive on cached numbers — not a short thesis.
Latest reported APVO revenue for 2022-12-31 was $3.1M. Net income was $8.0M. APVO currently screens at market cap $9.9M.
APVO currently screens at market cap $9.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next APVO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the APVO stock page for the full model, not this heading.
Not investment advice.